Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer

Allan Lipton, Richard J. Santen

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Twelve women with advanced breast carcinoma were given aminoglutethimide (up to 2 gm q.d. p.o.), in addition to dexamethasone (1.0–3.0 mg daily) and Florinef (0.1 mg b.i.w.) in order to produce a medical adrenalectomy. Adequacy of adrenal blockade was assessed by measuring A.M. plasma and 24‐hour urinary free cortisol by specific competitive protein binding techniques. Seven of 9 patients who had received an adequate trial had constant suppression of adrenal cortical function for at least a period of 8 weeks. Escape from blockade, when observed, was attributed to the rapid metabolism of dexamethasone induced by aminoglutethimide, demonstrated by determining the half‐life of 3H‐dexamethasone before and during treatment. Three patients with soft tissue involvement demonstrated a 1‐A response (12+, 5+ 6 months). Three patients with bone involvement showed a 0‐A response (7, 5, and 4 months). Lethargy and allergy to aminoglutethimide prevented an adequate trial in two patients. A third patient who was adequately suppressed for 7 weeks died before the 8‐week trial period. Minor side effects attributable to aminoglutethimide (nystagmus, ataxia, lethargy, skin rash) were seen frequently but abated with reduction in dosage. No Cushingoid side effects related to dexamethasone administration were noted.

Original languageEnglish (US)
Pages (from-to)503-512
Number of pages10
JournalCancer
Volume33
Issue number2
DOIs
StatePublished - Jan 1 1974

Fingerprint

Aminoglutethimide
Adrenalectomy
Dexamethasone
Breast Neoplasms
Lethargy
Competitive Binding
Ataxia
Exanthema
Protein Binding
Half-Life
Hydrocortisone
Hypersensitivity
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{0ea3b5ba015c4d98aacc9c3a47e5e570,
title = "Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer",
abstract = "Twelve women with advanced breast carcinoma were given aminoglutethimide (up to 2 gm q.d. p.o.), in addition to dexamethasone (1.0–3.0 mg daily) and Florinef (0.1 mg b.i.w.) in order to produce a medical adrenalectomy. Adequacy of adrenal blockade was assessed by measuring A.M. plasma and 24‐hour urinary free cortisol by specific competitive protein binding techniques. Seven of 9 patients who had received an adequate trial had constant suppression of adrenal cortical function for at least a period of 8 weeks. Escape from blockade, when observed, was attributed to the rapid metabolism of dexamethasone induced by aminoglutethimide, demonstrated by determining the half‐life of 3H‐dexamethasone before and during treatment. Three patients with soft tissue involvement demonstrated a 1‐A response (12+, 5+ 6 months). Three patients with bone involvement showed a 0‐A response (7, 5, and 4 months). Lethargy and allergy to aminoglutethimide prevented an adequate trial in two patients. A third patient who was adequately suppressed for 7 weeks died before the 8‐week trial period. Minor side effects attributable to aminoglutethimide (nystagmus, ataxia, lethargy, skin rash) were seen frequently but abated with reduction in dosage. No Cushingoid side effects related to dexamethasone administration were noted.",
author = "Allan Lipton and Santen, {Richard J.}",
year = "1974",
month = "1",
day = "1",
doi = "10.1002/1097-0142(197402)33:2<503::AID-CNCR2820330227>3.0.CO;2-L",
language = "English (US)",
volume = "33",
pages = "503--512",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. / Lipton, Allan; Santen, Richard J.

In: Cancer, Vol. 33, No. 2, 01.01.1974, p. 503-512.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer

AU - Lipton, Allan

AU - Santen, Richard J.

PY - 1974/1/1

Y1 - 1974/1/1

N2 - Twelve women with advanced breast carcinoma were given aminoglutethimide (up to 2 gm q.d. p.o.), in addition to dexamethasone (1.0–3.0 mg daily) and Florinef (0.1 mg b.i.w.) in order to produce a medical adrenalectomy. Adequacy of adrenal blockade was assessed by measuring A.M. plasma and 24‐hour urinary free cortisol by specific competitive protein binding techniques. Seven of 9 patients who had received an adequate trial had constant suppression of adrenal cortical function for at least a period of 8 weeks. Escape from blockade, when observed, was attributed to the rapid metabolism of dexamethasone induced by aminoglutethimide, demonstrated by determining the half‐life of 3H‐dexamethasone before and during treatment. Three patients with soft tissue involvement demonstrated a 1‐A response (12+, 5+ 6 months). Three patients with bone involvement showed a 0‐A response (7, 5, and 4 months). Lethargy and allergy to aminoglutethimide prevented an adequate trial in two patients. A third patient who was adequately suppressed for 7 weeks died before the 8‐week trial period. Minor side effects attributable to aminoglutethimide (nystagmus, ataxia, lethargy, skin rash) were seen frequently but abated with reduction in dosage. No Cushingoid side effects related to dexamethasone administration were noted.

AB - Twelve women with advanced breast carcinoma were given aminoglutethimide (up to 2 gm q.d. p.o.), in addition to dexamethasone (1.0–3.0 mg daily) and Florinef (0.1 mg b.i.w.) in order to produce a medical adrenalectomy. Adequacy of adrenal blockade was assessed by measuring A.M. plasma and 24‐hour urinary free cortisol by specific competitive protein binding techniques. Seven of 9 patients who had received an adequate trial had constant suppression of adrenal cortical function for at least a period of 8 weeks. Escape from blockade, when observed, was attributed to the rapid metabolism of dexamethasone induced by aminoglutethimide, demonstrated by determining the half‐life of 3H‐dexamethasone before and during treatment. Three patients with soft tissue involvement demonstrated a 1‐A response (12+, 5+ 6 months). Three patients with bone involvement showed a 0‐A response (7, 5, and 4 months). Lethargy and allergy to aminoglutethimide prevented an adequate trial in two patients. A third patient who was adequately suppressed for 7 weeks died before the 8‐week trial period. Minor side effects attributable to aminoglutethimide (nystagmus, ataxia, lethargy, skin rash) were seen frequently but abated with reduction in dosage. No Cushingoid side effects related to dexamethasone administration were noted.

UR - http://www.scopus.com/inward/record.url?scp=0016211635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016211635&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197402)33:2<503::AID-CNCR2820330227>3.0.CO;2-L

DO - 10.1002/1097-0142(197402)33:2<503::AID-CNCR2820330227>3.0.CO;2-L

M3 - Article

VL - 33

SP - 503

EP - 512

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -